India ▾

Prevest Denpro Limited — Q4 FY26 earnings call

Quarter ended 30 Jun 2026

Company page: Prevest Denpro share price, financials & guidance record

Management summary

Prevest Denpro reported a resilient FY26 with revenue from operations growing 13.9% to INR 71.81 crores, driven by strong export growth of 17.58%. Despite a challenging global environment and geopolitical tensions impacting Q4 and delaying UAE operations, the company maintained healthy profitability with an FY26 EBITDA margin of 38.6% and a Q4 EBITDA margin of 40.87%. Strategic focus on digital dentistry, including 3D printers and resins, showed significant growth, and the US market expanded by 37.58%.

Highlights

  • Revenue from operations for FY26 increased by 13.9% to INR 71.81 crores.

  • Export business recorded a growth of 17.58% during FY26.

  • EBITDA for FY26 increased by 13.3% to INR 29.62 crores.

  • Q4 FY26 EBITDA margin improved to 40.87%.

  • US market business grew by 37.58% in FY26, driven by Axiodent and private labeling.

  • 3D printer sales increased by 162% YoY, and 3D printing resins grew by 40.5%.

Concerns

  • FY26 margin moderated marginally compared to the previous year.

  • Global business environment remained challenging throughout FY26 due to tariff-related developments, geopolitical tensions, and conflict.

  • Q4 FY26 revenue growth was modest (2.63%) due to high geopolitical tensions, war-related developments, and supply chain disruptions.

  • Commercial operations of the UAE subsidiary were delayed due to geopolitical tensions and conflict in the Middle East.

  • Oradox business sales were down by 2% due to US market regulatory changes (Modernization of Cosmetic Regulations Act) and Dubai Municipality issues post-war.

Key financials

2 periods

Q4 FY26

  • Revenue from Operations
    ₹18.94 Cr
    YoY +2.6%
  • EBITDA
    ₹8.32 Cr
    YoY +9.1%
  • EBITDA Margin
    40.9%

FY26

  • Revenue from Operations
    ₹71.81 Cr
    YoY +13.9%
  • Total Income
    ₹76.72 Cr
    YoY +14.4%
  • EBITDA
    ₹29.62 Cr
    YoY +13.3%
  • PBT
    ₹27.61 Cr
    YoY +13.9%
  • PAT
    ₹20.49 Cr
    YoY +12.9%
  • EBITDA Margin
    38.6%
  • PAT Margin
    26.7%

What they filed

Q1 FY27: revenue up 20.9%, net profit up 27.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue16 15 18 16 19 +15%18 +23%19 +3%19 +21%
EBITDA6 5 7 5 7 +15%6 +11%7 +6%7 +27%
Net profit5 5 5 4 6 +15%5 +4%6 +13%6 +28%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Product Development

  • Indigenous 3D printer development Product Development · by 2028 · High confidence Totally indigenous 3D printer
    We are also actively working on the 3D printer project as well, so that we have a totally indigenous 3D printer by 2028.

    — Sai Kalyan, Director of Research and Academics

Product Launches

  • New Oradox product launches Product Launches · this year · High confidence 2 or 3 new products
    There are some new products also coming into the market. We expect 2 or 3 new product launches.

    — Sai Kalyan, Director of Research and Academics

Sales Growth

  • Oradox sales recovery Sales Growth · this year · High confidence compensate this loss
    We are down by 2%. That is because we couldn't export to the markets in the US... So, there's a small drop of just 2%. So, we will compensate this loss this year.

    — Sai Kalyan, Director of Research and Academics

OEM Business

  • OEM client expansion OEM Business · next 2 years · Medium confidence another big couple of companies
    And in the next 2 years, we expect to OEM for another big couple of companies.

    — Sai Kalyan, Director of Research and Academics

What to watch in Q1 FY27

UAE Subsidiary Commercial Operations

Next quarter / coming years
Current Delayed due to geopolitical tensions
Target Gradual commencement of operations

Why it matters

Crucial for expanding international footprint and contributing to long-term growth.

As the digital situation continues to stabilize, we expect to gradually commence operations and are confident that the UAE subsidiary will play an important role in expanding our international footprint and contributing to our long-term growth in the coming years.

Risks & concerns

  • Geopolitical Tensions and Conflict

    high

    Impacted UAE subsidiary launch, Q4 revenue, international trade, logistics, and customer ordering patterns, leading to a 2% decline in Oradox sales.

    Management acknowledged

  • Regulatory Changes in US Market

    medium

    The Modernization of Cosmetic Regulations Act in the US prevented exports, contributing to a 2% decline in Oradox sales.

    Management acknowledged

  • Supply Chain Disruption

    medium

    Disrupted customer ordering patterns and export dispatches in Q4 FY26.

    Management acknowledged

  • Competition from MNCs in Digital Dentistry

    medium

    Management believes they are slightly ahead in digital dentistry and leverage cost advantage and OEM strategy against larger players.

    Analyst addressed

  • Inflationary Pressures

    low

    Successfully mitigated through operational excellence and disciplined cost management to maintain healthy profitability.

    Management acknowledged

Q&A highlights

6 direct
Growth slowdown and reasons Direct
if you see that our company is growing 17%, 18% this year, which is a very positive thing if you see that if the countries in Asian market were suffering because of geopolitical changes, we got the opportunity of taking our business from the other countries.

Addresses investor concern about perceived growth slowdown by highlighting strong current year growth despite geopolitical challenges and market diversification.

Asked by Rahul Sharma

R&D spend as percentage of revenue Partial
We don't have the exact number yet. I will pass on the exact number to you. But R&D has done a lot of progress in this last couple of years, leading to product developments, 2 products. We are finished the regulatory pathway, and we have secured licenses and hit the market this month, 4 test licenses for new agents have been done...

Management could not provide the exact R&D spend percentage but detailed significant R&D progress and new product pipeline, indicating strategic investment.

Asked by Rahul Sharma

Subsidiary performance (Dubai and US) and purpose Direct
First question, I will start from Axiodent subsidiary in USA. there is a significant sale growth of U.S. market. Last -- in comparison to last year, we have grown the business in U.S. 37.58%... Dubai subsidiary, we have opened in the month of February and only. So, in March, this crisis happened. But still, we have employed 2 persons there as a sales manager.

Clarifies the strategic role and initial performance of key international subsidiaries, highlighting strong US growth and challenges/progress in Dubai.

Asked by Yash Modi

Current capacity utilization Direct
As far as the capacity utilization is concerned, the traditional capacity, the company is working at a capacity utilization of, say, around 67% to 68% of its total installed capacity. And if the company works with total installed capacity, the total turnover would be around, say, INR125 crores. And as far as the new production line is concerned, which includes digital dentistry, resin, disinfectants, oral health and all these, the company is working at, say, around 18% to 20% and very likely to increase the capacity utilized in the coming years.

Provides specific numbers on current and potential capacity utilization, indicating headroom for growth, especially in new product lines.

Asked by Yash Modi

Steps taken to increase domestic sales Direct
in the last 1 year, we have taken multiple steps to strengthen our presence in the market. The first step that we started was with the expansion of our distribution network. We started moving into the Tier 2 and Tier 3 cities... Then the next step that we took upon was to increase our product portfolio. That is where we got into disinfectants, Rotoflex and this thing.

Details the multi-pronged strategy for domestic market expansion, including distribution, sales team, and product portfolio enhancements.

Asked by Yash Modi

Traction and sales growth in Oradox business Direct
The Oradox business is doing reasonably good... We are down by 2%. That is because we couldn't export to the markets in the US. US started a new portal called the Modernization of Cosmetic Regulations Act. And the Dubai Municipality and after the war, we couldn't export substantial amounts.

Reveals a sales decline in the Oradox business and attributes it to specific regulatory and geopolitical challenges, providing transparency on a segment's performance.

Asked by Ajay Shah

3D printing use case, competitive advantage, and sales breakdown Direct
when it comes to the digital dentistry, everyone is at the same level. Probably we are slightly ahead than the other MNCs... So that is you can see around 40% increase in the revenue this year on 3D printing resins. We are also actively working on the 3D printer project as well, so that we have a totally indigenous 3D printer by 2028... We are selling printers also, sir... We are selling printers under the brand name Omni. And 3D printers... we have seen an increase in sales by around 162%... Yes, and 3D resins 40.5%.

Provides a comprehensive overview of the company's strategy and performance in the high-growth digital dentistry segment, including competitive positioning and specific growth numbers for printers and resins.

Asked by Ajay Shah

2 min read 7 chapters

Detailed narrative

FY26 Performance Overview

Prevest Denpro delivered a year of steady growth and disciplined execution in FY26, despite a challenging global business environment. Revenue from operations increased by 13.9% to INR 71.81 crores, up from INR 63.03 crores in FY25. The company maintained healthy profitability with an EBITDA of INR 29.62 crores, growing 13.3%, and an EBITDA margin of 38.6%. Domestic business grew by 9%, while the export business recorded a robust growth of 17.58%.

Q4 FY26 Performance & Challenges

The fourth quarter of FY26 was particularly challenging due to high geopolitical tensions, war-related developments, and disruptions in global shipping and supply chains. Despite these headwinds, revenue from operations increased by 2.63% to INR 18.94 crores. Profitability remained strong, with EBITDA growing 9.09% to INR 8.32 crores, and the EBITDA margin improved to 40.87%, demonstrating the company's ability to protect margins under difficult market conditions.

International Expansion & UAE Subsidiary

A significant initiative in FY26 was the establishment of a wholly-owned subsidiary in the UAE, aimed at strengthening regional presence. Commercial operations were delayed due to geopolitical tensions in the Middle East, but the company expects gradual commencement as the situation stabilizes. In contrast, the US market showed strong performance, with business growing 37.58% in FY26 through the Axiodent subsidiary, exhibitions, and private labeling arrangements.

New Verticals: Disinfectant Business

Prevest Denpro commenced commercialization of its disinfectant business during the year, marking a new vertical aligned with the rising demand for hygiene-driven products in dental and medical settings. The initial customer response has been highly encouraging, validating both market needs and product strength. The company plans to continue investing in expanding the reach and product portfolio of this business in a disciplined and phased manner.

Digital Dentistry & 3D Printing

Innovation in digital dentistry remains a core growth strategy, with the company expanding capabilities beyond its established 3D printing materials portfolio. Significant progress was made in developing next-generation digital solutions, including 3D printers, through a combination of in-house R&D and strategic collaborations. 3D printer sales increased by 162% YoY, and 3D printing resins grew by 40.5%. The company aims to develop a totally indigenous 3D printer by 2028.

Oradox Business & Product Launches

The Oradox oral care business experienced a 2% sales decline in FY26, primarily due to challenges in exporting to the US market (due to the Modernization of Cosmetic Regulations Act) and Dubai (post-war issues). Management is actively working to improve traction through marketing campaigns, direct doctor engagement, and expects 2-3 new product launches this year to boost sales and compensate for the current year's loss.

Operational Excellence & Domestic Market Strategy

The company maintained its focus on operational excellence, improving manufacturing processes, capacity utilization, and supply chain. This helped mitigate inflationary pressures and maintain profitability. Domestically, the company strengthened its presence by expanding its distribution network into Tier 2 and Tier 3 cities, adding sales team members, and enhancing its product portfolio with offerings like disinfectants and Rotoflex.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls